GSK1572932A
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for GSK1572932A, covering 2017-05-15 to 2019-01-30. Get the full timeline:
Most recent: Clinical Trial Update: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer [Phase 3]